EA202190601A1 - АНТИТЕЛА АНТИ-Fc ЭПСИЛОН-R1 АЛЬФА (FCER1A), БИСПЕЦИФИЧЕСКИЕ АНТИГЕНСВЯЗЫВАЮЩИЕ МОЛЕКУЛЫ, СВЯЗЫВАЮЩИЕ FCΕR1Α И CD3, И ИХ ПРИМЕНЕНИЕ - Google Patents
АНТИТЕЛА АНТИ-Fc ЭПСИЛОН-R1 АЛЬФА (FCER1A), БИСПЕЦИФИЧЕСКИЕ АНТИГЕНСВЯЗЫВАЮЩИЕ МОЛЕКУЛЫ, СВЯЗЫВАЮЩИЕ FCΕR1Α И CD3, И ИХ ПРИМЕНЕНИЕInfo
- Publication number
- EA202190601A1 EA202190601A1 EA202190601A EA202190601A EA202190601A1 EA 202190601 A1 EA202190601 A1 EA 202190601A1 EA 202190601 A EA202190601 A EA 202190601A EA 202190601 A EA202190601 A EA 202190601A EA 202190601 A1 EA202190601 A1 EA 202190601A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- epsilon
- alpha
- antibodies
- binding
- bispecific antigen
- Prior art date
Links
- 102100038006 High affinity immunoglobulin epsilon receptor subunit alpha Human genes 0.000 title 1
- 101000878611 Homo sapiens High affinity immunoglobulin epsilon receptor subunit alpha Proteins 0.000 title 1
- 206010002198 Anaphylactic reaction Diseases 0.000 abstract 1
- 206010020751 Hypersensitivity Diseases 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 230000007815 allergy Effects 0.000 abstract 1
- 230000036783 anaphylactic response Effects 0.000 abstract 1
- 208000003455 anaphylaxis Diseases 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 208000037765 diseases and disorders Diseases 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 230000008685 targeting Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862721921P | 2018-08-23 | 2018-08-23 | |
| PCT/US2019/047601 WO2020041537A1 (en) | 2018-08-23 | 2019-08-22 | Anti-fc epsilon-r1 alpha (fcer1a) antibodies, bispecific antigen-binding molecules that bind fcer1a and cd3, and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA202190601A1 true EA202190601A1 (ru) | 2021-07-14 |
Family
ID=67876086
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA202190601A EA202190601A1 (ru) | 2018-08-23 | 2019-08-22 | АНТИТЕЛА АНТИ-Fc ЭПСИЛОН-R1 АЛЬФА (FCER1A), БИСПЕЦИФИЧЕСКИЕ АНТИГЕНСВЯЗЫВАЮЩИЕ МОЛЕКУЛЫ, СВЯЗЫВАЮЩИЕ FCΕR1Α И CD3, И ИХ ПРИМЕНЕНИЕ |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US11578127B2 (enExample) |
| EP (1) | EP3840841A1 (enExample) |
| JP (2) | JP7402223B2 (enExample) |
| KR (1) | KR20210049863A (enExample) |
| CN (1) | CN112888482B (enExample) |
| AU (1) | AU2019325565B2 (enExample) |
| BR (1) | BR112021003023A2 (enExample) |
| CA (1) | CA3109513A1 (enExample) |
| CL (2) | CL2021000437A1 (enExample) |
| CO (1) | CO2021003608A2 (enExample) |
| EA (1) | EA202190601A1 (enExample) |
| IL (1) | IL280745A (enExample) |
| MX (1) | MX2021002165A (enExample) |
| MY (1) | MY204368A (enExample) |
| PH (1) | PH12021550322A1 (enExample) |
| SG (1) | SG11202101608XA (enExample) |
| WO (1) | WO2020041537A1 (enExample) |
| ZA (1) | ZA202100919B (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3840841A1 (en) | 2018-08-23 | 2021-06-30 | Regeneron Pharmaceuticals, Inc. | Anti-fc epsilon-r1 alpha (fcer1a) antibodies, bispecific antigen-binding molecules that bind fcer1a and cd3, and uses thereof |
| WO2021159128A2 (en) * | 2020-01-31 | 2021-08-12 | Randy Leiman Allen | Methods and kit for detection of analytes |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| DE122004000008I1 (de) | 1991-06-14 | 2005-06-09 | Genentech Inc | Humanisierter Heregulin Antikörper. |
| BRPI0515589A (pt) | 2004-09-02 | 2008-07-29 | Genentech Inc | polipeptìdeos ou anticorpos de ligação de antìgeno isolado, anticorpo isolado, método para regular de forma negativa a atividade de fc(gama)riib, métodos de tratamento, anticorpos biespecìficos isolados, métodos de inibição de uma resposta imune, de supressão na liberação de histamina, de ativação de fc(gama)riib, de inibição da expressão do receptor fc(épsilon)ri, composição e kit |
| NZ573557A (en) | 2006-06-02 | 2010-08-27 | Regeneron Pharma | High affinity antibodies to human il-6 receptor |
| SI2975051T1 (sl) | 2009-06-26 | 2021-08-31 | Regeneron Pharmaceuticals, Inc. | Zlahka izolirana bispecifična protitelesa z nativnim imunoglobulinskim formatom |
| DK2505654T4 (da) | 2010-02-08 | 2020-07-27 | Regeneron Pharma | Mus med fælles letkæde |
| WO2012142286A1 (en) * | 2011-04-12 | 2012-10-18 | University Of Cincinnati | Methods for suppressing allergic reactions |
| WO2012169741A2 (ko) | 2011-06-07 | 2012-12-13 | (주)네오팜 | ＦｃεＲＩ 특이적 인간 항체 및 이를 포함하는 알레르기 질환 치료 또는 진단용 조성물 |
| JOP20200236A1 (ar) * | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
| TWI635098B (zh) | 2013-02-01 | 2018-09-11 | 再生元醫藥公司 | 含嵌合恆定區之抗體 |
| EP2837637A1 (en) | 2013-08-16 | 2015-02-18 | SuppreMol GmbH | Novel anti-FcyRIIB IgG-type antibody |
| CN104293738A (zh) | 2013-09-11 | 2015-01-21 | 李莉 | 一种抗人FcεRⅠα亚基单克隆抗体及其应用 |
| EP2982693A1 (en) * | 2014-08-07 | 2016-02-10 | Affimed Therapeutics AG | CD3 binding domain |
| AU2015303142B2 (en) | 2014-08-13 | 2020-08-06 | Suppremol Gmbh | Novel antibodies directed to Fc gamma receptor IIB and Fc epsilon receptor |
| CN104800164B (zh) | 2015-04-13 | 2017-11-07 | 上海市第一人民医院 | 一种雷公藤免疫纳米粒及用途 |
| AU2016325630B2 (en) | 2015-09-23 | 2022-11-17 | Regeneron Pharmaceuticals, Inc. | Optimized anti-CD3 bispecific antibodies and uses thereof |
| EP3443006B1 (en) | 2016-04-13 | 2023-08-02 | Sanofi | Trispecific and/or trivalent binding proteins |
| PT3515946T (pt) | 2016-09-23 | 2022-08-04 | Regeneron Pharma | Anticorpos anti-muc16 (mucin 16) |
| EP3840841A1 (en) | 2018-08-23 | 2021-06-30 | Regeneron Pharmaceuticals, Inc. | Anti-fc epsilon-r1 alpha (fcer1a) antibodies, bispecific antigen-binding molecules that bind fcer1a and cd3, and uses thereof |
-
2019
- 2019-08-22 EP EP19765582.2A patent/EP3840841A1/en active Pending
- 2019-08-22 WO PCT/US2019/047601 patent/WO2020041537A1/en not_active Ceased
- 2019-08-22 MX MX2021002165A patent/MX2021002165A/es unknown
- 2019-08-22 US US16/547,910 patent/US11578127B2/en active Active
- 2019-08-22 CN CN201980069380.5A patent/CN112888482B/zh active Active
- 2019-08-22 EA EA202190601A patent/EA202190601A1/ru unknown
- 2019-08-22 MY MYPI2021000853A patent/MY204368A/en unknown
- 2019-08-22 JP JP2021510030A patent/JP7402223B2/ja active Active
- 2019-08-22 AU AU2019325565A patent/AU2019325565B2/en active Active
- 2019-08-22 KR KR1020217008580A patent/KR20210049863A/ko not_active Ceased
- 2019-08-22 BR BR112021003023-9A patent/BR112021003023A2/pt unknown
- 2019-08-22 CA CA3109513A patent/CA3109513A1/en active Pending
- 2019-08-22 SG SG11202101608XA patent/SG11202101608XA/en unknown
-
2021
- 2021-02-09 IL IL280745A patent/IL280745A/en unknown
- 2021-02-10 ZA ZA2021/00919A patent/ZA202100919B/en unknown
- 2021-02-15 PH PH12021550322A patent/PH12021550322A1/en unknown
- 2021-02-19 CL CL2021000437A patent/CL2021000437A1/es unknown
- 2021-03-19 CO CONC2021/0003608A patent/CO2021003608A2/es unknown
-
2023
- 2023-01-12 US US18/153,522 patent/US12441797B2/en active Active
- 2023-02-13 CL CL2023000442A patent/CL2023000442A1/es unknown
- 2023-10-03 JP JP2023172194A patent/JP7541167B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023171909A (ja) | 2023-12-05 |
| CN112888482A (zh) | 2021-06-01 |
| ZA202100919B (en) | 2025-10-29 |
| AU2019325565B2 (en) | 2025-09-04 |
| US20230331845A1 (en) | 2023-10-19 |
| WO2020041537A1 (en) | 2020-02-27 |
| BR112021003023A2 (pt) | 2021-05-11 |
| US11578127B2 (en) | 2023-02-14 |
| US12441797B2 (en) | 2025-10-14 |
| US20200062844A1 (en) | 2020-02-27 |
| CL2021000437A1 (es) | 2021-09-03 |
| CL2023000442A1 (es) | 2023-11-24 |
| WO2020041537A8 (en) | 2020-09-10 |
| NZ772900A (en) | 2025-05-02 |
| JP2021533806A (ja) | 2021-12-09 |
| SG11202101608XA (en) | 2021-03-30 |
| CN112888482B (zh) | 2024-06-25 |
| CA3109513A1 (en) | 2020-02-27 |
| IL280745A (en) | 2021-04-29 |
| MX2021002165A (es) | 2021-07-16 |
| PH12021550322A1 (en) | 2021-10-04 |
| AU2019325565A1 (en) | 2021-03-11 |
| JP7402223B2 (ja) | 2023-12-20 |
| KR20210049863A (ko) | 2021-05-06 |
| JP7541167B2 (ja) | 2024-08-27 |
| MY204368A (en) | 2024-08-26 |
| CO2021003608A2 (es) | 2021-04-30 |
| EP3840841A1 (en) | 2021-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA202191580A1 (ru) | Биспецифичные антитела анти-cd28 x анти-cd22 и их применение | |
| MX2025005515A (es) | Anticuerpos anti-bcma x anti-cd3 biespecificos y usos de estos | |
| EA201590613A1 (ru) | Антитела против cd3, биспецифические антигенсвязывающие молекулы, которые связываются с cd3 и cd20, и их применения | |
| EA201990781A9 (ru) | Анти-steap2 антитела, конъюгаты антитело-лекарственное средство и биспецифические антигенсвязывающие молекулы, которые связывают steap2 и cd3, и их применение | |
| MX2020013804A (es) | Anticuerpos anti-psma x anti-cd28 biespecíficos y usos de estos. | |
| SA522431672B1 (ar) | Cd3 أجسام مضادة للارتباط بـ | |
| EA201691858A1 (ru) | Композиции антител для лечения опухолей | |
| BR112022009317A2 (pt) | Anticorpos de cd73 biparatópicos | |
| EA201890785A1 (ru) | Оптимизированные биспецифические анти-cd3 антитела и их применение | |
| EA201890368A1 (ru) | Антитела против псма, биспецифичные антигенсвязывающие молекулы, которые связывают псма и cd3, и их применение | |
| EA201992402A1 (ru) | Антитела против ilt4 и антигенсвязывающие фрагменты | |
| EA202091569A1 (ru) | Моноклональные антитела и способы их применения | |
| EA202190601A1 (ru) | АНТИТЕЛА АНТИ-Fc ЭПСИЛОН-R1 АЛЬФА (FCER1A), БИСПЕЦИФИЧЕСКИЕ АНТИГЕНСВЯЗЫВАЮЩИЕ МОЛЕКУЛЫ, СВЯЗЫВАЮЩИЕ FCΕR1Α И CD3, И ИХ ПРИМЕНЕНИЕ | |
| EA202192907A1 (ru) | Моноклональное антитело, которое специфически связывается с gitr | |
| MX2023012300A (es) | Anticuerpos humanos contra artemina y metodos de uso de estos. | |
| Pörtner et al. | T and NK cells of B cell NHL patients exert cytotoxicity against lymphoma cells following binding of bispecific tetravalent antibody CD19× CD3 or CD19× CD16 | |
| CR20230245A (es) | Moléculas de unión a gucy2c y sus usos | |
| EA202190314A1 (ru) | Биспецифические анти-bcma x анти-cd3 антитела и способы их применения | |
| EA202191677A1 (ru) | Биспецифичные антитела анти-muc16 x анти-cd28 и варианты их применения | |
| EA202190089A1 (ru) | Биспецифичные антитела анти-psma x анти-cd28 и их применения | |
| MX2025010217A (es) | Anticuerpos multiespecificos anti-cd3 y metodos de uso | |
| TW202545991A (zh) | 抗ｃｄ２８抗體及其用途 | |
| TH2101000210A (th) | ไบสเปซิฟิกแอนติ-BCMA x แอนติ-CD3 แอนติบอดี และการใช้แอนติบอดีดังกล่าว | |
| EA201991227A1 (ru) | Антитела против cd3, биспецифические антигенсвязывающие молекулы, которые связываются с cd3 и cd20, и их применения | |
| MX2024006573A (es) | Anticuerpos b7-h4 y anticuerpo anti-b7-h4/ proteinas de fusion il-15. |